Protocol 2: significant weight loss (20-25% body weight) Goal: Substantial weight reduction for health improvement Tirzepatide approach: Full escalation to 10-15 mg Expect to reach target dose by week 17-21 Weight loss at 15 mg: approximately 22.5% at 72 weeks Plateau typically occurs around weeks 60-72 Retatrutide approach: Full escalation to 8-12 mg Expect to reach target dose by week 13-17 Weight loss at 12 mg: 24.2% at 48 weeks, 28.7% at 68 weeks No plateau observed in trial data at 48 or 68 weeks For significant weight loss goals, retatrutide reaches 20%+ body weight reduction faster and ultimately achieves a higher ceiling
Sections 503A and 503B of the FD&C Act allow pharmacies and registered outsourcing facilities (facilities registered with the FDA under Section 503B that may compound larger volumes of drugs without individual patient prescriptions), respectively, to compound customized medications but not copies of commercially available drugs, unless those drugs are on the FDAs shortage list (a publicly available, regularly updated database identifying drugs whose national supply cannot meet current demand)
As for its preventive capacity, studies have suggested a possible protective role of high VC intake with reduced colorectal cancer (84, 85), stomach cancer (86, 87), and pancreatic cancer (88)
In a human gastric adenocarcinoma cell line, melatonin reduced MMP activity [196]
